Finding progesterone in several kinds of medicine can make them seem like convenient alternatives: swallow a capsule, use a vaginal product or apply something to the skin. That impression leaves out how the preparation delivers the ingredient and what purpose was actually studied. The route is part of the medicine's identity, not an optional packaging detail.
This guide compares the scope of named product records without providing a conversion or substitution. It also explains why evidence from fertility care does not automatically settle a menopause question. The aim is to help you recognize when a website has changed products, populations or treatment goals while continuing to use the same hormone name.
Read this article by section
Start with the full medicine, then identify its intended purpose
Record the name, manufacturer, dosage form and labeled route before interpreting a benefit claim. Capsule, insert and gel describe different preparations. The same word gel can also be incomplete without the route: a product intended for vaginal use is not identified merely by its consistency or by being applied rather than swallowed.
The Prometrium, Endometrin and Crinone records each name a particular progesterone preparation. They also describe different clinical settings. A study's treatment purpose should travel with its result when it appears in a review. Ask what the participants were being treated for and what outcome was measured; the ingredient alone cannot tell you whether the study answers the question relevant to the proposed prescription.
Oral Prometrium has a defined label, not every possible progesterone use
The current Prometrium record identifies oral capsules and includes prevention of endometrial hyperplasia in a specified postmenopausal population receiving conjugated estrogens tablets. It also includes treatment of secondary amenorrhea. These are defined uses, with contraindications, precautions and evidence attached to the product.
That record should not be rewritten as approval of every capsule for every estrogen combination. Nor should the word oral be removed when its evidence is summarized. The CoreAge review examines a separately advertised compounded oral offer, whose full preparation is not established by the brand-name record. An evidence review needs to preserve that distinction even when both descriptions use micronized progesterone and both are discussed in the context of hormone care.
Endometrin's current indication is a specific fertility indication
The Endometrin record updated in July 2026 describes a progesterone vaginal insert within assisted reproductive technology, or ART. Its current indication specifies support of embryo implantation in infertile women younger than 35 through supplementation of corpus luteal function, with support during a specified early-pregnancy period after implantation. That population and purpose are substantially different from a menopause endometrial-protection question.
Do not remove the age and ART context when describing what this label establishes. Evidence from that preparation cannot, by itself, prove that a vaginal product protects the uterine lining within a different hormone plan. This article does not recommend Endometrin, describe its administration or give a fertility-treatment schedule. The example demonstrates how a familiar ingredient can appear in evidence that answers an entirely different clinical question.
Crinone shows why route alone still does not finish the identification
Crinone's label describes a bioadhesive vaginal progesterone gel. It includes ART progesterone supplementation or replacement and specified secondary-amenorrhea uses, with distinctions between its formulations and the relevant clinical circumstances. It is not simply another name for a progesterone vaginal insert, and a gel label is not a general endorsement of all vaginal progesterone use.
A discussion that groups every vaginal study together may hide differences in formulation, population and outcome. Ask which product was used and whether the evidence concerns pregnancy support, restoration of bleeding in a particular condition or another purpose. Those endpoints do not become interchangeable because the route is shared. Our terminology guide applies the same discipline to ingredient and hormone-family names.
Skin creams cannot borrow protection claims from oral or vaginal products
For compounded progesterone applied through the skin, the British Menopause Society's May 2026 guidance raises concern about variable absorption and potentially insufficient endometrial protection. This is UK professional guidance, not approval of a US product. It provides a reason to examine the evidence carefully, not a formula for estimating a cream's exposure or replacing a prescribed medicine.
A comforting skin texture, a claimed hormone concentration or the word natural cannot establish that a preparation achieves a required clinical effect. The FDA's compounding explanation also makes clear that a compounded product lacks FDA premarket approval review. If a cream is proposed for an endometrial-protection role, ask the clinician to explain the evidence for that actual preparation and purpose instead of relying on a general progesterone description.
A clinician's off-label recommendation needs an explicit explanation
An approved product may sometimes be prescribed outside its labeled use. The FDA's off-label guidance explains that this can include a different condition or way of administration, but FDA has not determined safety and effectiveness for that unapproved use. That is distinct from a compounded medicine that is itself unapproved.
If a proposed route or purpose differs from the label you find, ask the prescriber to explain the rationale and supporting evidence. Do not change the route yourself because another page reports that the same hormone was used differently. Our approval guide separates these regulatory questions, while the micronization guide explains why a physical ingredient descriptor cannot supply a missing route-specific clinical assessment.
Keep comparisons tied to the exact treatment question
Before accepting a review's conclusion, check whether it kept the product, route, population and outcome consistent. If any of those changed, the review should say what can and cannot be inferred. Our offers comparison distinguishes provider descriptions from identified product records; it does not convert a fertility result or a skin-cream claim into evidence for a different oral offer.
Progesterone Particulars is part of the CoreAge Rx promotional publishing network, explaining CoreAge's commercial first placement. That affiliation provides no basis for route substitution or claims of equivalent protection. The next useful step is a clear explanation from the prescriber and dispensing pharmacist about the actual preparation, its intended role and the evidence supporting that choice.
Documents behind the details
Read the source for the product, use and context it actually describes. A source type is not a rating of a provider.
- DailyMed: Prometrium, Acertis Pharmaceuticals, updated July 23, 2026Prescribing information · Checked 2026-09-27
- DailyMed: Endometrin progesterone vaginal insert, updated July 29, 2026Exact product labeling · Checked 2026-09-27
- DailyMed: Crinone progesterone vaginal gel, updated May 21, 2024Exact product labeling · Checked 2026-09-27
- British Menopause Society: Progestogens and endometrial protection, May 2026UK medical society clinician guidance · Checked 2026-09-27
- FDA: Understanding the risks of compounded drugsRegulatory guidance · Checked 2026-09-27
- FDA: Understanding Unapproved Use of Approved DrugsFederal regulator explanation · Checked 2026-09-27